Evidence map›Paper›PMID 27621205›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2016

Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics.

Bhagwat Prasad, Katherine Johnson, Sarah Billington, Caroline Lee, Git W Chung, Colin D A Brown, Edward J Kelly, Jonathan Himmelfarb, Jashvant D Unadkat

Open access · bronzeAbstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 136 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Use of a Double-Transfected System to Predict hOCT2/hMATE1-Mediated Renal Drug-Drug Interactions.Drug metabolism and disposition: the biological fate of chemicals · 2024
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Bhagwat PrasadDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.).
Katherine JohnsonDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.).
Sarah BillingtonDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.).
Caroline LeeDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.).
Git W ChungDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.).
Colin D A BrownDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.).
Edward J KellyDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.).
Jonathan HimmelfarbDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.).
Jashvant D UnadkatDepartment of Pharmaceutics, University of Washington, Seattle, Washington (B.P., K.J., S.B., E.J.K., J.D.U.); Ardea Biosciences, San Diego, California (C.L.); Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom (G.W.C., C.D.A.B); and Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington (J.H.). jash@u.washington.edu.
Newcastle University · GBUniversity of Washington · US

Funding

Understanding Fetal Exposure to Cannabinoids Through In Vitro and In Vivo StudiesP01DA032507 · NIDA · UNIVERSITY OF WASHINGTON · PI UNADKAT, JASHVANT D · 2013 to 2023
$12.4M
Using iPSCs to model patient outcomes in nephrotic syndromeUH3TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2014 to 2016
$6.1M
A Tissue Engineered Human Kidney Microphysiological SystemUH2TR000504 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2012 to 2013
$2.1M
National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/C013112/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/K500240/1NCATS NIH HHS UH2 TR000504NCATS NIH HHS UH3 TR000504NIDA NIH HHS P01 DA032507
6 · The paper itself

Abstract

Protein expression of renal uptake and efflux transporters was quantified by quantitative targeted proteomics using the surrogate peptide approach. Renal uptake transporters assessed in this study included organic anion transporters (OAT1-OAT4), organic cation transporter 2 (OCT2), organic/carnitine cation transporters (OCTN1 and OCTN2), and sodium-glucose transporter 2 (SGLT2); efflux transporters included P-glycoprotein, breast cancer resistance protein, multidrug resistance proteins (MRP2 and MRP4), and multidrug and toxin extrusion proteins (MATE1 and MATE2-K). Total membrane was isolated from the cortex of human kidneys (N = 41). The isolated membranes were digested by trypsin and the digest was subjected to liquid chromatography-tandem mass spectrometry analysis. The mean expression of surrogate peptides was as follows (given with the standard deviation, in picomoles per milligram of total membrane protein): OAT1 (5.3 ± 1.9), OAT2 (0.9 ± 0.3), OAT3 (3.5 ± 1.6), OAT4 (0.5 ± 0.2), OCT2 (7.4 ± 2.8), OCTN1 (1.3 ± 0.6), OCTN2 (0.6 ± 0.2), P-glycoprotein (2.1 ± 0.8), MRP2 (1.4 ± 0.6), MRP4 (0.9 ± 0.6), MATE1 (5.1 ± 2.3), and SGLT2 (3.7 ± 1.8). Breast cancer resistance protein (BCRP) and MATE2-K proteins were detectable but were below the lower limit of quantification. Interestingly, the protein expression of OAT1 and OAT3 was significantly correlated (r > 0.8). A significant correlation was also observed between expression of multiple other drug transporters, such as OATs/OCT2 or OCTN1/OCTN2, and SGLT2/OCTNs, OCT, OATs, and MRP2. These renal transporter data should be useful in deriving in vitro to in vivo scaling factors to accurately predict renal clearance and kidney epithelial cell exposure to drugs or their metabolites.

Indexed as

AdultBiological TransportCell MembraneFemaleHumansKidney CortexMaleMembrane ProteinsMembrane Transport ProteinsPharmaceutical PreparationsProteomicsMembrane ProteinsMembrane Transport ProteinsPharmaceutical Preparations

Identifiers

PMID27621205
PMCPMC5118637
OpenAlexW2521008236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.